REFERENCES
1. Roberts E, Howell S, Evans DG. Polygenic risk scores and breast cancer risk prediction. Breast 2023;67:71-7.
2. Purrahman D, Mahmoudian-Sani MR, Saki N, Wojdasiewicz P, Kurkowska-Jastrzębska I, Poniatowski ŁA. Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer. Cytokine 2022;151:155803.
3. Tung N, Ricker C, Messersmith H, et al. Selection of germline genetic testing panels in patients with cancer: ASCO guideline. J Clin Oncol 2024;42:2599-615.
4. Di Rado S, Giansante R, Cicirelli M, et al. Detection of germline mutations in a cohort of 250 relatives of mutation carriers in multigene panel: impact of pathogenic variants in other genes beyond BRCA1/2. Cancers 2023;15:5730.
5. Anaclerio F, Pilenzi L, Dell’Elice A, et al. Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis. Front Genet 2023;14:1060504.
6. Mavaddat N, Michailidou K, Dennis J, et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet 2019;104:21-34.
7. Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention. Nat Rev Cancer 2020;20:417-36.
8. Evans DGR, van Veen EM, Harkness EF, et al. Breast cancer risk stratification in women of screening age: incremental effects of adding mammographic density, polygenic risk, and a gene panel. Genet Med 2022;24:1485-94.
9. Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res 2010;1:109-26.
10. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res 2017;50:33.
11. Michailidou K, Lindström S, Dennis J, et al. Association analysis identifies 65 new breast cancer risk loci. Nature 2017;551:92-4.
12. Milne RL, Kuchenbaecker KB, Michailidou K, et al. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 2017;49:1767-78.
13. Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. Hum Mol Genet 2019;28:R133-42.
14. Visscher PM, Wray NR, Zhang Q. et al. 10 years of GWAS discovery: biology, function, and translation. Am J Hum Genet 2017;101:5-22.
15. Allman R, Dite GS, Hopper JL, et al. SNPs and breast cancer risk prediction for African American and Hispanic women. Breast Cancer Res Treat 2015;154:583-9.
16. Dite GS, MacInnis RJ, Bickerstaffe A, et al. Breast cancer risk prediction using clinical models and 77 independent risk-associated snps for women aged under 50 years: Australian breast cancer family registry. Cancer Epidemiol Biomarkers Prev 2016;25:359-65.
17. Dite GS, Mahmoodi M, Bickerstaffe A, et al. Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model. Breast Cancer Res Treat 2013;139:887-96.
18. Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 2019;21:1708-18.
19. Shieh Y, Hu D, Ma L, et al. Breast cancer risk prediction using a clinical risk model and polygenic risk score. Breast Cancer Res Treat 2016;159:513-25.
20. Li H, Feng B, Miron A, et al. Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. Genet Med 2017;19:30-5.
21. Laderian B, Zhou M, Fojo T. Distribution of cancer genes in human chromosomes. Semin Oncol 2020;47:409-13.
22. Sud A, Turnbull C, Houlston R. Will polygenic risk scores for cancer ever be clinically useful? NPJ Precis Oncol 2021;5:40.
23. Wang Y, Zhu M, Ma H, Shen H. Polygenic risk scores: the future of cancer risk prediction, screening, and precision prevention. Med Rev 2021;1:129-49.
24. Taylor LC, Law K, Hutchinson A, Dennison RA, Usher-Smith JA. Acceptability of risk stratification within population-based cancer screening from the perspective of healthcare professionals: a mixed methods systematic review and recommendations to support implementation. PLoS One 2023;18:e0279201.
25. Ho WK, Tan MM, Mavaddat N, et al. European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. Nat Commun 2020;11:3833.
26. Mavaddat N, Pharoah PDP, Michailidou K, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 2015;107:djv036.
27. Ho PJ, Ho WK, Khng AJ, et al. Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification. BMC Med 2022;20:150.
28. Li J, Ugalde-Morales E, Wen WX, et al. Differential burden of rare and common variants on tumor characteristics, survival, and mode of detection in breast cancer. Cancer Res 2018;78:6329-38.
29. Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci 2017;13:1387-97.
30. Jantzen R, Payette Y, de Malliard T, Labbé C, Noisel N, Broët P. Validation of breast cancer risk assessment tools on a French-Canadian population-based cohort. BMJ Open 2021;11:e045078.
31. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
32. Farkas A, Vanderberg R, Merriam S, DiNardo D. Breast cancer chemoprevention: a practical guide for the primary care provider. J Womens Health 2020;29:46-56.
33. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004;23:1111-30.
34. Karsono R, Haryono SJ, Karsono B, Harahap WA, Pratiwi Y, Aryandono T. ESR1 PvuII polymorphism: from risk factor to prognostic and predictive factor of the success of primary systemic therapy in advanced breast cancer. BMC Cancer 2021;21:1348.
35. Markiewicz A, Wełnicka-Jaśkiewicz M, Skokowski J, et al. Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients. PLoS One 2013;8:e72219.
36. Reinert T, Saad ED, Barrios CH, Bines J. Clinical implications of ESR1 mutations in hormone receptor-positive advanced breast cancer. Front Oncol 2017;7:26.
37. Yu J, Wang CG. Relationship between polymorphisms in homologous recombination repair genes RAD51 G172T, XRCC2 & XRCC3 and risk of breast cancer: a meta-analysis. Front Oncol 2023;13:1047336.
38. Castro E, Olmos D, Garcia A, Cruz JJ, González-Sarmiento R. Role of XRCC3, XRCC1 and XPD single-nucleotide polymorphisms in survival outcomes following adjuvant chemotherapy in early stage breast cancer patients. Clin Transl Oncol 2014;16:158-65.
39. Goričar K, Dugar F, Dolžan V, Marinko T. NBN, RAD51 and XRCC3 polymorphisms as potential predictive biomarkers of adjuvant radiotherapy toxicity in early HER2-positive breast cancer. Cancers 2022;14:4365.
40. Klein RJ, Gümüş ZH. Are polygenic risk scores ready for the cancer clinic? - a perspective. Transl Lung Cancer Res 2022;11:910-9.
41. Junior HLR, Novaes LAC, Datorre JG, Moreno DA, Reis RM. Role of polygenic risk score in cancer precision medicine of non-European populations: a systematic review. Curr Oncol 2022;29:5517-30.
42. Evans DG, van Veen EM, Byers H, et al. The importance of ethnicity: are breast cancer polygenic risk scores ready for women who are not of white European origin? Int J Cancer 2022;150:73-9.
43. Liu C, Zeinomar N, Chung WK, et al. Generalizability of polygenic risk scores for breast cancer among women with European, African, and Latinx Ancestry. JAMA Netw Open 2021;4:e2119084.
44. Jia G, Ping J, Guo X, et al. Genome-wide association analyses of breast cancer in women of African ancestry identify new susceptibility loci and improve risk prediction. Nat Genet 2024;56:819-26.
45. Coignet MV, Zirpoli GR, Roberts MR, et al. Genetic variations, reproductive aging, and breast cancer risk in African American and European American women: the women’s circle of health study. PLoS One 2017;12:e0187205.
46. Dixon P, Keeney E, Taylor JC, Wordsworth S, Martin RM. Can polygenic risk scores contribute to cost-effective cancer screening? A systematic review. Genet Med 2022;24:1604-17.
47. Dannhauser FC, Taylor LC, Tung JSL, Usher-Smith JA. The acceptability and clinical impact of using polygenic scores for risk-estimation of common cancers in primary care: a systematic review. J Commun Genet 2024;15:217-34.
48. Lopes Cardozo JMN, Andrulis IL, Bojesen SE, et al. Associations of a breast cancer polygenic risk score with tumor characteristics and survival. J Clin Oncol 2023;41:1849-63.
49. Yiangou K, Mavaddat N, Dennis J, et al. Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction. medRxiv 2024.
